GONADOTROPIN, CHORIONIC for PCOS
GONADOTROPIN, CHORIONIC is an early-phase (EARLY_PHASE_1) clinical candidate for PCOS acting as a luteinizing hormone/choriogonadotropin receptor agonist per Open Targets.
Hypothesized mechanism
By agonizing the LH/choriogonadotropin receptor, chorionic gonadotropin may mimic the LH surge to support ovulation and ovarian function in PCOS.
This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.
How the score was reached, for this pair
The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 6 of 10 overall, a moderate reading, from a pathway rated moderate in strength.
The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.
Scored for women. Evidence generated in women (female population). (band F1, ×1.00).
Corroboration
Only one line of mechanistic evidence is provided: a single Open Targets annotation stating that GONADOTROPIN, CHORIONIC acts as a luteinizing hormone/choriogonadotropin receptor agonist and is an early-phase clinical candidate for PCOS. There are no independent converging mechanistic sources.
Rigor
The claim derives from a curated database annotation citing an EARLY_PHASE_1 clinical candidate status, which implies human-relevant context but provides no actual study data, model details, or trial outcomes. The evidence is a target-association record rather than a rigorous mechanistic study.
Specificity
The mechanism of action is explicitly defined as a luteinizing hormone/choriogonadotropin receptor agonist acting on the named LH/CG receptor target, indicating high specificity of the drug's action on a defined target.
Plausibility
LH/CG receptor agonism is mechanistically relevant to ovulation induction and ovarian function in PCOS, supporting target-phenotype fit. However, the single claim does not describe how this agonism translates to a PCOS phenotypic benefit, limiting the strength of the plausibility assessment.
Consistency
With only a single mechanistic statement, there is no opportunity for multiple signals to align or conflict; the lone annotation is internally consistent but cannot demonstrate convergence.
Layers not covered for this pair
Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.
More on the sex-specific pharmacokinetics layer and its sources →Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.
More on the cycle-phase layer and its sources →Source evidence · what the pipeline ingested
These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).
Every source below belongs to this signal’s evidence arm, Pathway insights. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.
- 1Per Open Targets (retrieved 2026-06-16), GONADOTROPIN, CHORIONIC (a Protein) is a clinical candidate for PCOS (maximum clinical stage EARLY_PHASE_1); its mechanism of action is Luteinizing hormone/Choriogonadotropin receptor agonist on target luteinizing hormone/choriogonadotropin receptor. Open Targets · mechanistic ↗
These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.
The primary sources and pipelines this evidence is drawn from →